GeneDx Announces Heidi Chen as Chief Legal Officer and Corporate Secretary

WGSWW 11.18.2024

Full Press ReleaseSEC FilingsOur WGSWW Tweets

About Gravity Analytica

Recent News

  • 01.17.2025 - GeneDx Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
  • 01.16.2025 - 43rd Annual J.P. Morgan Healthcare Conference
  • 01.13.2025 - GeneDx Announces Preliminary 2024 Financial Results

Recent Filings

  • 01.22.2025 - 4 Statement of changes in beneficial ownership of securities
  • 01.13.2025 - 3 Initial statement of beneficial ownership of securities
  • 01.13.2025 - EX-99.1 EX-99.1

Veteran Legal Executive from Zoetis and Pfizer Joins GeneDx Executive Leadership Team to Lead Legal, Compliance and Policy Functions

STAMFORD, Conn.--(BUSINESS WIRE)--Nov. 18, 2024--GeneDx(Nasdaq: WGS), a leader in delivering improved health outcomes through genomic insights, today announced the appointment ofHeidi Chenas Chief Legal Officer, effectiveNovember 25, 2024. In her role, Heidi will report toKatherine Stueland, CEO and President, and will serve on the executive leadership team.

With over 30 years of experience, Heidi will lead all legal, compliance, and policy functions atGeneDxand will provide strategic counsel on corporate governance, intellectual property, regulatory matters, federal policy, compliance and more.

“With a massive transformation behind us and a clear runway for growth ahead, Heidi brings the expertise and leadership needed to guideGeneDxinto this next chapter, particularly given the changing landscape in healthcare,” said Stueland. “Heidi is a celebrated and well-respected business leader and general counsel who brings extensive industry expertise toGeneDx. I’m happy to welcome Heidi to our executive leadership team to shape our business and legal strategy to advance critical initiatives to drive innovation as we enter this next phase of growth for our business.”

Heidi joinsGeneDxfrom Zoetis, where she served as General Counsel for nearly 12 years, a role she assumed following the company’s spinoff from Pfizer in 2013. During her tenure at Zoetis, she was instrumental in building the company’s legal department and establishing essential processes to support the company’s rapid growth. Heidi also oversaw global security, enterprise risk management, M&A, litigation and all corporate governance. In addition to her legal oversight, she also led operational strategy for a specialized human health diagnostics segment within the Zoetis business. Prior to the spinoff Heidi held a variety of leadership positions on Pfizer’s legal team and worked across compliance, litigation, licensing and risk management. She began her career with roles at Hughes & Hubbard andClifford Chance. Heidi holds a J.D. fromCornell Law Schooland a B.S. fromYale University.

“I’m honored to have the opportunity to help accelerate GeneDx’s growth and continue transforming patient care,” said Chen. “I look forward to collaborating with the talented team atGeneDxto push boundaries, drive disruptive change, and pioneer innovations that deliver meaningful improvements in health outcomes.”

AboutGeneDx:GeneDx(Nasdaq: WGS) delivers personalized and actionable health insights to inform diagnosis, direct treatment, and improve drug discovery. The company is uniquely positioned to accelerate the use of genomic and large-scale clinical information to enable precision medicine as the standard of care.GeneDxis at the forefront of transforming healthcare through its industry-leading exome and genome testing and interpretation services, fueled by the world’s largest, rare disease data sets. For more information, please visitwww.genedx.comand connect with us onLinkedIn,Facebook, andInstagram.

View source version onbusinesswire.com:https://www.businesswire.com/news/home/20241118085768/en/

Press@genedx.comInvestors@genedx.com

Source:GeneDx

Please be aware that the following content has been generated by an AI system and may contain errors, inconsistencies, or outdated information. It is provided as-is without any warranties or guarantees of accuracy. We strongly recommend using this content as a starting point for further research and consultation with relevant experts or authorities. We disclaim any liability for damages or losses resulting from the use or reliance on this content.Please note that this is a beta version of the Gravity Analytica LLC’s AI Service which isstill undergoing final testing before its official release. Theplatform, its software and all content found on it are provided on an“as is” and “as available” basis. Gravity Analytica LLC does not give any warranties,whether express or implied, as to the suitability or usability of thisservice, webpage, or its software or any of its content.Should you encounter any bugs, glitches, lack of functionality orother problems on the website, please let us know immediately so wecan rectify these accordingly. Your help in this regard is greatlyappreciated! You can write to us at this addressteam@gravityanalytica.com